Editas Medicine (NASDAQ: EDIT) — Perfil da empresa, notícias e dados financeiros
Editas Medicine is pioneering gene editing technology to develop transformative medicines for serious genetic diseases.
Editas Medicine
Editas Medicine (NASDAQ:EDIT) is a pioneer in gene editing technology, striving to develop transformative medicines for people living with serious diseases. The company harnesses the power of CRISPR, a cutting-edge gene editing tool, to target and potentially cure a wide range of genetic disorders. Editas Medicine's operations span from research and development to the clinical trial phase for its various projects, with a primary focus on delivering life-changing treatments. Among their notable initiatives is the advancement of gene editing therapies for the treatment of inherited retinal diseases, blood disorders, and cancer. Committed to innovation and excellence, Editas Medicine aims to redefine medicine by unlocking the potential of gene editing to provide durable, and possibly curative, treatments.
Resumo
Operações
Produtos e/ou serviços de Editas Medicine
- CRISPR/Cas9 gene editing platform, a revolutionary technology enabling precise genome editing.
- EDIT-101 for Leber Congenital Amaurosis 10 (LCA10), targeting a gene mutation causing a form of inherited blindness.
- EDIT-301 designed for the treatment of Sickle Cell Disease and Beta-Thalassemia, aiming to increase fetal hemoglobin production.
- In Vivo Gene Editing projects, focusing on directly editing genes within the human body to treat diseases.
- Ex Vivo Gene Editing therapies for various conditions, involving the modification of cells outside the body then reintroducing them.
- Research collaborations with leading pharmaceutical companies to explore new gene editing therapies and applications.
equipe executiva do Editas Medicine
- Gilmore O'NeillPresident, CEO & Director
- Amy ParisonSenior VP & CFO
- Linda C. BurklyExecutive VP & Chief Scientific Officer
- Feng ZhangCo-Founder & Scientific Advisory Board Member
- George McDonald ChurchCo-Founder & Scientific Advisory Board Member
- Gregory WhiteheadExecutive VP and Chief Technical & Quality Officer
- Damien GriersonSenior VP, General Counsel & Corporate Secretary
- Tom LoveVice President of People
- Frank PanaccioSenior VP & Chief Business Officer
- Brieana BuckleySenior Vice President of Development and Program Leadership
Últimas notícias sobre a Editas Medicine
Principais indicadores financeiros
Resultados divulgados pela Editas Medicine, em USD.
- Cap. de mercado
- 453,1 mi
- Receita (TTM)
- 47 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.7
- Dividend yield
- —
- Margem de lucro
- -157.3%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 40,5 mi | -99,3 mi | -160,1 mi | |
| 32,3 mi | -251,2 mi | -237,1 mi | |
| 78,1 mi | -169,2 mi | -153,2 mi | |
| 19,7 mi | -226 mi | -204,4 mi |